Ambalal Sarabhai Enterprises Limited has filed a mandatory compliance certificate with BSE Limited under SEBI regulations for the quarter ended March 31, 2026. The submission, dated April 9, 2026, fulfills regulatory requirements under the SEBI (Depositories and Participants) Regulations, 2018.

Regulatory Compliance Filing

The company submitted the certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. This regulation mandates listed companies to provide confirmation certificates regarding dematerialization processes handled during each quarter.

Certificate Confirmation

MCS Share Transfer Agent Limited, serving as the company's Registrar and Transfer Agent, issued the confirmation certificate on April 8, 2026. The certificate confirms several critical compliance aspects:

• Securities received from depository participants for dematerialization were properly confirmed to depositories
• All securities comprised in certificates have been listed on stock exchanges where earlier issued securities are listed
• Security certificates received for dematerialisation were mutilated and cancelled after due verification
• Depository names were substituted in the register of members as registered owners within the mandated 15-day period

Corporate Governance

Ms. Disha Punjani, Company Secretary and Compliance Officer (F13158), signed the submission on behalf of Ambalal Sarabhai Enterprises Limited. The filing demonstrates the company's commitment to maintaining regulatory compliance and proper corporate governance practices.

Registrar and Transfer Agent Details

MCS Share Transfer Agent Limited, located at Shatdal Complex, Ashram Road, Ahmedabad, serves as the company's registrar. The agent confirmed all dematerialization processes were completed in accordance with SEBI regulations and within prescribed timelines.

This routine compliance filing ensures transparency in securities handling and maintains investor confidence in the company's adherence to regulatory frameworks governing depositories and participant operations.

Ambalal Sarabhai Enterprises Limited (ASE) has reported mixed financial results for the second quarter ended September 30, with a consolidated net loss despite relatively stable revenue.

Key Financial Highlights

Revenue Performance

ASE reported a marginal decline in consolidated revenue from operations, which stood at Rs 4,444.92 lakhs for Q2, compared to Rs 4,470.41 lakhs in the same quarter last year, representing a slight decrease of 0.57%.

Profitability

The company experienced a significant downturn in profitability, reporting a consolidated net loss of Rs 56.03 lakhs for the quarter, in contrast to a profit of Rs 261.99 lakhs in Q2 of the previous year. This represents a substantial decline of 121.39% year-over-year.

Segment Performance

ASE operates in two business segments:

1. Pharmaceuticals: This segment reported revenue of Rs 2,601.39 lakhs, with a segment result of Rs (121.14) lakhs before interest and finance costs.
2. Electronics: The electronics segment generated revenue of Rs 1,843.53 lakhs, with a segment result of Rs 213.37 lakhs before interest and finance costs.

Half-Year Performance

For the half-year ended September 30:

• Consolidated revenue reached Rs 8,478.80 lakhs
• Net profit stood at Rs 766.32 lakhs

Balance Sheet Highlights

As of September 30:

• Total assets: Rs 26,019.34 lakhs
• Total equity: Rs 13,752.35 lakhs
• Cash and cash equivalents: Rs 177.36 lakhs

Management Commentary

The Board of Directors approved these unaudited financial results in their meeting held on November 12. The company's management has not provided specific comments on the performance in the given data.

Outlook

While ASE has maintained relatively stable revenue, the shift from profit to loss in Q2 may raise concerns. Investors and stakeholders will likely be watching closely to see how the company addresses this profitability challenge in the coming quarters.

The company's performance in its two main segments shows contrasting results, with the Electronics segment remaining profitable while the Pharmaceuticals segment reported a loss. This may prompt a closer examination of segment-specific strategies going forward.

Investors should note that these are unaudited results, and the final audited figures may differ.